moneyheap
PBH · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Prestige Consumer Healthcare Inc. (PBH) stock moving?
Prestige reported Q2 FY2027 revenue of $336.3M and adjusted EPS of $1.13, beating estimates of $329.1M and $1.07. The beat was overshadowed by a cut to FY2027 guidance: adjusted EPS now $4.48-$4.55 versus $4.55-$4.65 before (midpoint about $4.52, below the $4.58 consensus), and sales $1.280B-$1.290B versus $1.290B-$1.315B before (midpoint about $1.285B, below the $1.298B estimate). The stock rallied 8.6% to $53.28 on Nov 4 on 800K shares, then fell 16.8% to $44.32 on Nov 5 on 1.72M shares, roughly three times the recent average. It has since traded between $43 and $45, with Nov 10 up 3.0% to $44.97 on lighter volume, leaving it below its late-October range of about $47-$50. Canaccord kept its Buy rating and cut its target to $70, which signals continued analyst support. The provided news does not explain the Nov 4 rally, and no catalyst is scheduled within the next week in the data provided.
News behind the analysis
- Prestige Consumer Lowers FY2027 Adj EPS Guidance from $4.55-$4.65 to $4.48-$4.55 vs $4.58 Est; Lowers FY2027 Sales Guidance from $1.290B-$1.315B to $1.280B-$1.290B vs $1.298B EstPrestige cut its FY2027 adjusted EPS and sales guidance, with the new EPS range sitting below the $4.58 consensus. The guidance cut came alongside a Q2 beat.
- Prestige Consumer Healthcare Reports Fiscal 2027 Second Quarter Financial ResultsQ2 FY2027 revenue came in at $336.3 million and adjusted diluted EPS at $1.13. Both figures topped the consensus estimates.
- Prestige Consumer Q2 Adj. EPS $1.13 Beats $1.07 Estimate, Sales $336.307M Beat $329.130M EstimateQ2 adjusted EPS of $1.13 beat the $1.07 estimate, and sales of $336.3M beat the $329.1M estimate. The quarter was a beat on both lines.
- Prestige Consumer Q2 2027 Earnings Call TranscriptTranscript of the Q2 FY2027 earnings call, held on Nov 5, where management discussed the quarter and the updated outlook.
- Canaccord Genuity Maintains Buy on Prestige Consumer, Lowers Price Target to $70Canaccord Genuity kept its Buy rating on PBH but lowered its price target to $70 after the results and guidance update.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is a Tarrytown, New York-based company with about 890 employees. It sells over-the-counter health and personal care brands such as Dramamine, Fleet, Monistat, Summer's Eve, Clear Eyes, Hydralyte, BC/Goody's and, since a June 2026 acquisition, Breathe Right. Its strategy is to buy established niche brands, outsource most of the manufacturing, and use the steady cash they produce to pay down debt, buy back shares and make more acquisitions.
How it makes money
It sells its branded OTC products mainly through US drugstores, mass-market retailers, grocery stores and online, with smaller businesses in Canada, Australia and other international markets. North America makes up the large majority of sales, roughly 85%. Major product groups include gastrointestinal (Dramamine, Fleet, Hydralyte), women's health (Monistat, Summer's Eve), eye and ear care (Clear Eyes, TheraTears, Debrox), analgesics, cough and cold, oral care (DenTek) and skin care. Revenue in fiscal 2026 (year ended March 2026) was about $1.09 billion, down roughly 4% partly because of Clear Eyes supply limits. Recent acquisitions, Breathe Right and Australia's LaCorium Health, have since increased quarterly sales.
What usually moves PBH
- Brand acquisitions and the debt used to fund them
- Supply-chain and manufacturing reliability (e.g., eye care supply limits)
- Strength of cough/cold season and consumer spending on OTC products
- Retailer inventory levels and private-label competition
- Free cash flow, share buybacks and debt leverage